Plain-English translation of NCT06039709 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing sonodynamic therapy, a new combination treatment that uses a medication called 5-ALA (Gleolan) together with low-intensity focused ultrasound (sound waves) to treat glioblastoma—a serious type of brain cancer—that has come back after initial treatment. The medication and sound waves work together to destroy tumor cells. This treatment would be given 1–3 weeks before your surgery to remove the tumor.
Glioblastoma is an aggressive brain cancer that often returns even after surgery, chemotherapy, and radiation. Doctors are looking for new ways to help control recurrent tumors and improve outcomes for patients who face this challenging diagnosis.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the sonodynamic therapy treatment (the medication and sound wave procedure) 1–3 weeks before your scheduled brain surgery. After the treatment, you will stay overnight in the hospital so doctors can monitor you for any side effects. Your participation includes having MRI scans with contrast dye, blood tests to check your health, and follow-up visits to track how you're doing.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States